User:327r/sandbox
| Submission declined on 15 April 2025 by Numberguy6 (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd is an Australian biotechnology company developing a new class of synthetic antibiotics designed to address antibiotic-resistant superbugs. The company’s lead candidate, RECCE® 327 (R327), is a broad-spectrum anti-infective under clinical development for conditions such as diabetic foot infections, acute bacterial skin and skin structure infections (ABSSSI), urinary tract infections, urosepsis, sepsis, and burn wound infections. Recce is publicly listed on the Australian Securities Exchange (ASX: RCE), and Frankfurt Stock Exchange (FSE: F9Q).
History
Recce Pharmaceuticals was founded following the discovery of RECCE® 327 by Dr Graham Melrose, who developed the compound while experimenting in his retirement at a home laboratory in Mount Claremont, Perth, Western Australia. The name “327” refers to “experimental book 3 – page 27”. Dr Melrose later brought the compound to the attention of family members James Graham and Michele Dilizia, who helped transition the research into a formal laboratory setting at Bentley Technology Park. In the early stages, James Graham supported capital raising initiatives, while Michele Dilizia contributed laboratory and scientific expertise.
Technology and Lead Compound
RECCE® 327 is a patented, wholly synthetic antibiotic developed to address the limitations of conventional antibiotics derived from natural sources. Unlike traditional antibiotics that typically target specific bacterial mechanisms, RECCE® 327 employs a non-specific mechanism of action that interferes with bacterial cellular metabolism and energy production at or near the cell surface, depleting ATP.
The compound targets and irreversibly binds to essential bacterial proteins, leading to rapid bactericidal action without inducing cell lysis. RECCE® 327 is both rapid and irreversibly bactericidal, effectively killing bacteria and providing a potent, long-lasting solution for bacterial infections.
Made up of millions of monomers bound into proprietary polymers, RECCE® 327 is 100% water-soluble at all pH levels. This unique synthetic structure provides broad-spectrum activity across multiple bacterial strains, including extensively drug-resistant (XDR) bacteria and "superbugs." In studies, RECCE® 327 has demonstrated consistent bactericidal activity, with no loss of efficacy after multiple exposures.
Clinical Development
RECCE® 327 has undergone a range of pre-clinical safety and efficacy studies in accordance with U.S. Food and Drug Administration (FDA) protocols. Clinical development programs are underway in Australia, and Indonesia.
Key areas of clinical focus include:
- Diabetic foot infections – Primary development focus. A Phase 3 clinical trial is currently underway in Indonesia, in partnership with PT Etana Biotechnologies
- ABSSSI (Acute Bacterial Skin and Skin Structure Infections)
- Urinary tract infections (UTIs) and urosepsis
- Burn wound infections – Supported by a U.S. Department of Defense grant program
- Sepsis
Manufacturing
Recce Pharmaceuticals operates a dedicated manufacturing facility in Australia. The company has developed an automated process to produce RECCE® 327 at scale in preparation for large-scale clinical use.
Strategic Partnerships
Recce has established partnerships to support its clinical pipeline and global development:
PT Etana Biotechnologies Indonesia – Partner for the Phase 3 trial in diabetic foot infections
U.S. Department of Defense – Collaboration through a grant program to develop R327 for burn wound applications
Board of Directors
Dr John Prendergast – Executive Chairman
James Graham – Managing Director & Chief Executive Officer
Michele Dilizia – Executive Director & Chief Scientific Officer
Dr Justin Ward – Executive Director & Principal Quality Chemist
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
Alistair McKeough – Non-Executive Director
Justin Reynolds – Outsourced CFO (Pitcher Partners Sydney)
Maggie Niewidok – Company Secretary
See Also
References
World Health Organization. Antibiotic Resistance.
Recce Pharmaceuticals Ltd. Company Announcements.
Australian Securities Exchange. ASX: RCE. Frankfurt Stock Exchange. FSE:R9Q